Sign up
Pharma Capital

Callitas Health promotes Joshua Maurice to sales VP

Maurice’s promotion comes as the clinical-stage pharmaceutical development group advances its programs and partnerships
desk
Callitas Health is developing innovative remedies for weight management, female sexual health, cannabis delivery and other proprietary drugs

Callitas Health Inc (CSE:LILY) (OTCQB:MPHMF) said Tuesday that Joshua Maurice has been promoted to vice-president of sales and business development.

Maurice’s promotion comes as the clinical-stage pharmaceutical development group adds to its management and hires consultants to advance its programs and partnerships and build on this year’s progress.

READ: Callitas Health banks on CannaStrips and OTC products while swinging for the fence with blockbuster drugs

“We’ve seen important strides in the first months of 2019 across the women’s health, cannabinoid and infertility spaces and deepening partnerships with companies like NFI Consumer Healthcare and Lifestyles,” said James Thompson, CEO of Callitas, in a statement.

“Promoting Joshua to this new position allows us to utilize his talents to further capitalize on these advancements in the company,” he added.

Formed in early 2015, Callitas Health is developing innovative remedies for weight management, female sexual health, cannabis delivery technologies and other proprietary drugs.

Callitas shares slipped a cent to hit $0.10 in New York trade on Tuesday morning.

Contact Ellen Kelleher at [email protected]

View full LILY profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.